Physician profile
Tamara K Hanby
NPI 1811055403
$5,819.81
in general payments reported to CMS, 2019-2025
40 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $737 · 2021: $1,474 · 2022: $991 · 2023: $467 · 2024: $499 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,276.68 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $534.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $456.58 | 2020-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $444.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $379.19 | 2024-2025 | Voquezna |
| Merz North America, INC. | $315.41 | 2020-2025 | Xeomin |
| Lilly USA, LLC | $291.14 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $210.45 | 2021-2022 | |
| Amarin Pharma, INC. | $185.56 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $148.95 | 2020-2021 | |
| Clarus Therapeutics INC. | $137.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.63 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $127.07 | 2021 | |
| Mannkind Corporation | $120.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $112.25 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Hanby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.